TrialRMD open2024

Comparison of the efficacy and safety of a proposed biosimilar MSB11456 with tocilizumab reference product in subjects with moderate-to-severe rheumatoid arthritis: results of a randomised double-blind study.

Anna Zubrzycka-Sienkiewicz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.